Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients by Amalia Azzariti, Simona De Summa, Tommaso M. Marvulli, Ivana De Risi, Giuseppe De Palma, Roberta Di Fonte, Rossella Fasano, Simona Serratì, Sabino Strippoli, Letizia Porcelli, Michele Guida

Subjects: Get full text

Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade by Ayana Yamagami, Shintaro Iwama, Tomoko Kobayashi, Xin Zhou, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Tetsushi Izuchi, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima

Subjects: “…pd-1…”
Get full text

Circulating T Cell Subsets in Type 1 Diabetes by Aldo Ferreira-Hermosillo, Paola Santana-Sánchez, Ricardo Vaquero-García, Manuel R. García-Sáenz, Angélica Castro-Ríos, Adriana K. Chávez-Rueda, Rita A. Gómez-Díaz, Luis Chávez-Sánchez, María V. Legorreta-Haquet

Subjects: Get full text

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells by Guochen Li, Haiyan Yang, Tengfei Ke, Na Tan, Xiaolan Du, Xirui Duan, Xinyan Zhou, Guangrong Zheng, Chengde Liao

Subjects: Get full text

Overcoming immune evasion with innovative multi-target approaches for glioblastoma by Hai Su, Yin Peng, Yilong Wu, Xiaoli Zeng, Xiaoli Zeng, Xiaoli Zeng

Subjects: Get full text

The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors by Xin Y, Liu N, Peng G, Huang X, Cao X, Zhou X

Subjects: Get full text

Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC by Gulizaina Hapaer, Feng Che, Qing Xu, Qian Li, Ailin Liang, Zhou Wang, Jituome Ziluo, Xin Zhang, Yi Wei, Yuan Yuan, Bin Song, Bin Song

Subjects: Get full text

Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma by Marek Pasek, Eva Sticová, Emanuel Marques, Vojtěch Tretera, Petr Arenberger, Monika Arenbergerová

Subjects: “…melanoma, anti-PD-1, anti-LAG-3, adverse events…”
Get full text

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies by Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang, Chencheng Han, Rui Liu, Chen Hu, Qingyu Wang, Jun Zhu, Yongqiang Shan

Subjects: “…Anti-PD-1/PD-L1…”
Get full text

Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma by Lin Zhang, Haoming Jiang, Haichao Ma

Subjects: Get full text

Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer by Yuanyuan Wang, Chenxi Hu, Tianpeng Du, Jiawen Li, Kaiyuan Hui, Xiaodong Jiang

Subjects: “…anti-PD-1…”
Get full text

Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition by Johannes M. Waldschmidt, Johannes M. Waldschmidt, Lukas Haug, Lukas Haug, Christine Riedhammer, Christine Riedhammer, Christoph K. W. Deinzer, Marcus Zimmermann, Marcus Zimmermann, Anke Heidemeier, Anke Heidemeier, Peter Raab, Peter Raab, Maximilian Rudert, Maximilian Rudert, Anne Hendricks, Anne Hendricks, Johan F. Lock, Johan F. Lock, Viktoria Buck, Viktoria Buck, Andreas Rosenwald, Andreas Rosenwald, Hermann Einsele, Hermann Einsele, Peter Reichardt, Volker Kunzmann, Volker Kunzmann, Armin Wiegering, Armin Wiegering, Daniel Pink, Daniel Pink, K. Martin Kortüm, K. Martin Kortüm

Subjects: Get full text

Thyroid Dysfunction After Intensity-Modulated Radiotherapy and PD⁃1 Inhibitor Treatment for Locally Advanced Nasopharyngeal Carcinoma by Shang K, He Q, Xu X, Luo X, Zhao C, Liu L, Li Z, Li Y, Jin F

Subjects: Get full text

Toxic epidermal necrolysis induced by nivolumab therapy for unresectable intraperitoneal cancer by Hiroyoshi Nozaki, Jiro Uehara, Naoki Kato, Masaru Honma, Akemi Ishida-Yamamoto

Subjects: Get full text

Emerging roles of checkpoint molecules on B cells by Hiromitsu Asashima, Satoshi Akao, Isao Matsumoto

Subjects: Get full text

Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4 by Zongyu Liu, Hongyu Chu, Weidong Zhao, Chenguang Yang, Tongjun Liu, Na Shen, Zhaohui Tang

Subjects: Get full text

Immune checkpoint inhibitor associated lichenoid dermatitis mimicking erythema multiforme major with a germline variant in human leukocyte antigen-B15 by Sach Thakker, BS, Alexis Antonucci, BS, Amin Benyounes, MD, Blair S. Allais, MD

Subjects: Get full text

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors by Dandan Yuan, Yali Gao, Lin Xia, Han Liu, Xingye Wu, Xueyan Ding, Yudan Huang, Changchun Deng, Jin Li, Wenqi Dai, Jieqing Liu, Junjie Ma

Subjects: “…PD-1/PD-L1…”
Get full text

Differences in the intrahepatic expression of immune checkpoint molecules on T cells and natural killer cells in chronic HBV patients by Lucile Dumolard, Marie-Noelle Hilleret, Marie-Noelle Hilleret, Charlotte Costentin, Charlotte Costentin, Marion Mercey-Ressejac, Marion Mercey-Ressejac, Nathalie Sturm, Nathalie Sturm, Theophile Gerster, Thomas Decaens, Thomas Decaens, Evelyne Jouvin-Marche, Patrice N. Marche, Zuzana Macek Jilkova, Zuzana Macek Jilkova

Subjects: Get full text

Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report by Shuangying Zhao, Xiaodong Zhang, Jialiang Luo, Huanjun Yan, Jianlei Zhang, Rongfeng Lin, Kelei Zhu

Subjects: Get full text